In a retrospective study of chemotherapy, naive breast cancer (n = 497) and ovarian cancer (n = 561) patients with known BRCA1/2 status were used to set the cut-off value at ≥42 [36]. This evidence concerns the gene BRCA1 and ovarian cancer.